vs
Side-by-side financial comparison of First Bancorp, Inc (FNLC) and ZEVRA THERAPEUTICS, INC. (ZVRA). Click either name above to swap in a different company.
ZEVRA THERAPEUTICS, INC. is the larger business by last-quarter revenue ($34.1M vs $25.8M, roughly 1.3× First Bancorp, Inc). On growth, ZEVRA THERAPEUTICS, INC. posted the faster year-over-year revenue change (183.4% vs 17.5%). First Bancorp, Inc produced more free cash flow last quarter ($34.6M vs $5.5M). Over the past eight quarters, ZEVRA THERAPEUTICS, INC.'s revenue compounded faster (215.7% CAGR vs 18.1%).
Patriot Bank, N.A. (PNBK) is the bank holding company for Stamford, Connecticut-based Patriot Bank NA, and is traded on NASDAQ as PNBK.
Zevra Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with rare under-treated orphan diseases, with a primary focus on central nervous system and metabolic rare disorder segments. Its main target markets are North America and the European Union.
FNLC vs ZVRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.8M | $34.1M |
| Net Profit | $10.2M | — |
| Gross Margin | — | — |
| Operating Margin | 48.1% | 27.3% |
| Net Margin | 39.4% | — |
| Revenue YoY | 17.5% | 183.4% |
| Net Profit YoY | 39.7% | — |
| EPS (diluted) | $0.91 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.8M | $34.1M | ||
| Q3 25 | $24.5M | $26.1M | ||
| Q2 25 | $22.5M | $25.9M | ||
| Q1 25 | $21.8M | $20.4M | ||
| Q4 24 | $22.0M | $12.0M | ||
| Q3 24 | $20.5M | $3.7M | ||
| Q2 24 | $19.2M | $4.4M | ||
| Q1 24 | $18.5M | $3.4M |
| Q4 25 | $10.2M | — | ||
| Q3 25 | $9.1M | $-544.0K | ||
| Q2 25 | $8.1M | $74.7M | ||
| Q1 25 | $7.1M | $-3.1M | ||
| Q4 24 | $7.3M | — | ||
| Q3 24 | $7.6M | $-33.2M | ||
| Q2 24 | $6.2M | $-19.9M | ||
| Q1 24 | $6.0M | $-16.6M |
| Q4 25 | 48.1% | 27.3% | ||
| Q3 25 | 45.2% | 15.9% | ||
| Q2 25 | 43.7% | -274.5% | ||
| Q1 25 | 39.3% | -26.3% | ||
| Q4 24 | 39.5% | -128.0% | ||
| Q3 24 | 44.6% | -739.0% | ||
| Q2 24 | 38.8% | -534.8% | ||
| Q1 24 | 39.3% | -598.1% |
| Q4 25 | 39.4% | — | ||
| Q3 25 | 37.0% | -2.1% | ||
| Q2 25 | 35.8% | 288.7% | ||
| Q1 25 | 32.5% | -15.2% | ||
| Q4 24 | 33.1% | — | ||
| Q3 24 | 36.9% | -899.2% | ||
| Q2 24 | 32.1% | -447.9% | ||
| Q1 24 | 32.5% | -485.3% |
| Q4 25 | $0.91 | — | ||
| Q3 25 | $0.81 | $-0.01 | ||
| Q2 25 | $0.72 | $1.21 | ||
| Q1 25 | $0.63 | — | ||
| Q4 24 | $0.66 | — | ||
| Q3 24 | $0.68 | $-0.69 | ||
| Q2 24 | $0.55 | $-0.48 | ||
| Q1 24 | $0.54 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $62.4M |
| Total DebtLower is stronger | $95.5M | $61.9M |
| Stockholders' EquityBook value | $283.1M | $154.7M |
| Total Assets | $3.2B | $284.7M |
| Debt / EquityLower = less leverage | 0.34× | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $62.4M | ||
| Q3 25 | — | $54.4M | ||
| Q2 25 | — | $47.7M | ||
| Q1 25 | — | $37.3M | ||
| Q4 24 | — | $33.8M | ||
| Q3 24 | — | $54.0M | ||
| Q2 24 | — | $39.3M | ||
| Q1 24 | — | $42.8M |
| Q4 25 | $95.5M | $61.9M | ||
| Q3 25 | $95.5M | $61.3M | ||
| Q2 25 | $95.0M | $60.7M | ||
| Q1 25 | $70.0M | — | ||
| Q4 24 | $95.0M | $59.5M | ||
| Q3 24 | $95.0M | — | ||
| Q2 24 | $70.0M | — | ||
| Q1 24 | $70.0M | — |
| Q4 25 | $283.1M | $154.7M | ||
| Q3 25 | $274.6M | $133.2M | ||
| Q2 25 | $265.5M | $117.2M | ||
| Q1 25 | $259.7M | $41.0M | ||
| Q4 24 | $252.5M | $39.7M | ||
| Q3 24 | $256.8M | $69.8M | ||
| Q2 24 | $244.7M | $32.5M | ||
| Q1 24 | $242.6M | $48.8M |
| Q4 25 | $3.2B | $284.7M | ||
| Q3 25 | $3.2B | $270.1M | ||
| Q2 25 | $3.2B | $256.3M | ||
| Q1 25 | $3.2B | $172.7M | ||
| Q4 24 | $3.2B | $178.1M | ||
| Q3 24 | $3.1B | $191.6M | ||
| Q2 24 | $3.1B | $144.4M | ||
| Q1 24 | $3.0B | $151.3M |
| Q4 25 | 0.34× | 0.40× | ||
| Q3 25 | 0.35× | 0.46× | ||
| Q2 25 | 0.36× | 0.52× | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | 1.50× | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.29× | — | ||
| Q1 24 | 0.29× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $37.8M | $5.5M |
| Free Cash FlowOCF − Capex | $34.6M | $5.5M |
| FCF MarginFCF / Revenue | 133.9% | 16.1% |
| Capex IntensityCapex / Revenue | 12.5% | 0.1% |
| Cash ConversionOCF / Net Profit | 3.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $55.3M | $-2.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.8M | $5.5M | ||
| Q3 25 | $12.9M | $4.7M | ||
| Q2 25 | $7.4M | $-3.6M | ||
| Q1 25 | $2.2M | $-8.2M | ||
| Q4 24 | $26.0M | $-16.3M | ||
| Q3 24 | $9.8M | $-18.1M | ||
| Q2 24 | $6.4M | $-19.1M | ||
| Q1 24 | $-1.5M | $-16.2M |
| Q4 25 | $34.6M | $5.5M | ||
| Q3 25 | $12.6M | $4.2M | ||
| Q2 25 | $7.2M | $-3.8M | ||
| Q1 25 | $828.0K | $-8.3M | ||
| Q4 24 | $24.6M | — | ||
| Q3 24 | $9.6M | — | ||
| Q2 24 | $6.3M | — | ||
| Q1 24 | $-1.8M | — |
| Q4 25 | 133.9% | 16.1% | ||
| Q3 25 | 51.4% | 15.9% | ||
| Q2 25 | 32.1% | -14.7% | ||
| Q1 25 | 3.8% | -40.8% | ||
| Q4 24 | 111.7% | — | ||
| Q3 24 | 47.0% | — | ||
| Q2 24 | 32.9% | — | ||
| Q1 24 | -9.8% | — |
| Q4 25 | 12.5% | 0.1% | ||
| Q3 25 | 1.2% | 2.1% | ||
| Q2 25 | 0.6% | 0.8% | ||
| Q1 25 | 6.2% | 0.5% | ||
| Q4 24 | 6.7% | 0.0% | ||
| Q3 24 | 0.5% | 0.0% | ||
| Q2 24 | 0.3% | 0.0% | ||
| Q1 24 | 1.8% | 0.0% |
| Q4 25 | 3.72× | — | ||
| Q3 25 | 1.42× | — | ||
| Q2 25 | 0.91× | -0.05× | ||
| Q1 25 | 0.31× | — | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 1.29× | — | ||
| Q2 24 | 1.03× | — | ||
| Q1 24 | -0.25× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FNLC
Segment breakdown not available.
ZVRA
| MIPLYFFA | $26.4M | 77% |
| Arimoclomol Purchase Agreement | $5.7M | 17% |
| Other | $2.0M | 6% |
